AI Article Synopsis
- The study evaluates the effectiveness of quantitative image analysis (QIA) compared to manual scoring by pathologists for important breast cancer biomarkers: estrogen receptor (ER), progesterone receptor (PgR), and HER2.
- A retrospective analysis of 1,367 invasive breast cancer cases revealed high concordance rates between QIA and manual scores (93% for ER, 96% for PgR, 90% for HER2), though some discrepancies were noted due to low scores or representation issues.
- The findings suggest that QIA is a reliable computer-aided tool that enhances standardization in biomarker scoring, but emphasizes the importance of pathologist oversight in selecting representative areas for analysis.
Article Abstract
Objectives: Biomarker expression evaluation for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) is an essential prognostic and predictive parameter for breast cancer and critical for guiding hormonal and neoadjuvant therapy. This study compared quantitative image analysis (QIA) with pathologists' scoring for ER, PgR, and HER2.
Methods: A retrospective analysis was undertaken of 1,367 invasive breast carcinomas, including all histopathology subtypes, for which ER, PgR, and HER2 were analyzed by manual scoring and QIA. The resulting scores were compared, and in a subset of HER2 cases (n = 373, 26%), scores were correlated with available fluorescence in situ hybridization (FISH) results.
Results: Concordance between QIA and manual scores for ER, PgR, and HER2 was 93%, 96%, and 90%, respectively. Discordant cases had low positive scores (1%-10%) for ER (n = 33), were due to nonrepresentative region selection (eg, ductal carcinoma in situ) or tumor heterogeneity for PgR (n = 43), and were of one-step difference (negative to equivocal, equivocal to positive, or vice versa) for HER2 (n = 90). Among HER2 cases where FISH results were available, only four (1.0%) showed discordant QIA and FISH results.
Conclusions: QIA is a computer-aided diagnostic support tool for pathologists. It significantly improves ER, PgR, and HER2 scoring standardization. QIA demonstrated excellent concordance with pathologists' scores. To avoid pitfalls, pathologist oversight of representative region selection is recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajcp/aqab206 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing core needle biopsy and surgical excision in breast cancer diagnosis: implications for clinical practice from a retrospective cohort study.
Quant Imaging Med Surg
December 2024
Department of Ultrasound, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University), Shenzhen, China.
Background: Preoperative ultrasound-guided core needle biopsy (CNB) is currently the standard procedure for managing breast illnesses. However, the differences in outcomes between CNB and surgical excision (SE) have not been thoroughly assessed. This study aimed to explore the disparities in pathological outcomes between these two procedures, using a large sample dataset.
View Article and Find Full Text PDFClinicopathological features and prognosis of breast cancer with low HER2 status evaluated by fluorescence hybridization.
Oncol Lett
February 2025
Department of Surgery, Teikyo University School of Medicine, Tokyo 173-8606, Japan.
Although trastuzumab deruxtecan improves the prognosis of patients with HER2-low breast cancer, the characteristics and prognostic value of low HER2 status remains to be elucidated. A prospective database of patients with clinical stage I to III breast cancer who underwent surgery between September 2012 and October 2022 at Teikyo University Hospital (Tokyo, Japan) were analyzed. HER2 was evaluated using fluorescence hybridization assay, and HER2-low and HER2-negative was defined as HER2/CEP17 ratio ≥1.
View Article and Find Full Text PDFImpact of Warm Ischemia Time on HER2 Expression in Breast Cancer Surgical Specimens.
Anticancer Res
December 2024
Department of Surgery, Yokohama City University, Yokohama, Japan.
Article Synopsis
- * A study involving 277 breast cancer patients examined the effects of WIT, CIT, and FT on the expression of estrogen receptors (ER), progesterone receptors (PgR), and HER2 in surgical specimens compared to preoperative biopsies.
- * Findings showed that while ER and PgR expressions tended to decrease with longer CIT and FT, only HER2 expression was significantly affected by WIT exceeding 30 minutes, indicating the importance of
Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- breast cancer.
Ann Diagn Pathol
February 2025
Department of Breast and Thyroid Surgery, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. Electronic address:
Oncotype DX is the only multigene assay supported by the National Comprehensive Cancer Network (USA) with Level 1 evidence for use on node-negative and postmenopausal node-positive patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)-breast cancer to predict the prognosis and to estimate chemotherapy add-on effects. However, the test's high cost prevents its use in most cases. Therefore, we aimed to obtain an alternative recurrence score (RS) prediction formula using the optimal clinicopathological factors.
View Article and Find Full Text PDF[Long-Term Response to CDK4/6 Inhibitor for Multiple Metastases of Breast Cancer].
Gan To Kagaku Ryoho
October 2024
Dept. of Breast and Endocrine Surgery, Nippon Dental University Hospital.
The patient was a 60-year-old woman. She was diagnosed with hypertension, symptomatic epilepsy, renal failure, and cerebral infarction. During follow-up, she was found to have a mass in her left breast and was referred to our department.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!